Gilead Sciences (GILD) has been the focus of various investment activities, market movements and adjustments, and notable medical research findings. The company's
ROE has drawn attention, falling weaker than the industry standards. Wells Fargo reiterated an
Overweight rating for GILD, while other investors sold off significant shares, such as Meyer Handelman's reduced holding by 12,485 shares. On the innovation front, GILD showcased impressive medical developments including a new shot which blocks 99.9% of HIV infections and
US FDA approval for an inflammatory liver disease drug. However, the company faced a setback with the recall of one lot of their COVID-19 treatment due to the presence of glass particles.
Financial results for the third quarter of 2024 are set to be released on Wednesday, November 6, 2024. Currently, GILD's
stock performance follows confused patterns, with reports of both declines and advancements offsetting the general market trend. Barclays and JPMorgan raised price targets, while GILD also experienced insider stock sales.
Gilead Sciences GILD News Analytics from Tue, 02 Apr 2024 07:00:00 GMT to Sat, 12 Oct 2024 13:27:40 GMT -
Rating 0
- Innovation 5
- Information 7
- Rumor -2
